|
|
StreetInsider.com
May 14
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Management+Changes/Affymax+%28AFFY%29+CEO+to+Be+Replaced+by+Rep+of+Restructuring+Firm/8338007.html for the full story.
StreetInsider.com
May 9
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/Affymax++%28AFFY%29+Reports+Q1+Loss+of+%240.71/8324472.html for the full story.
StreetInsider.com
May 8
Comment
TORM (Nasdaq: TRMD) 70.4% HIGHER; in part, reported Q1 EBITDA of $36 million, from a negative $7 million reported in the same period last year.
Affymax, Inc. (Nasdaq: AFFY) 34.8% HIGHER; continuing higher as earnings for the company are expected...
The Market Financial
May 7
Comment
Hammered small cap biotech stocks are jumping today, another sign investors are searching for anything with even a faint pulse to buy. Affymax, Inc. (NASDAQ:AFFY) is trading at $1.10, +0.30 (37.48%) and Celsion Corporation (NASDAQ:CLSN) is trading...
StreetInsider.com
Apr 23
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Affymax+%28AFFY%29+Enters+Consulting+Agreement+with+Brenner+Group/8272545.html for the full story.
StreetInsider.com
Apr 11
Comment
This report is an intraday check of some of the more notable stocks that have hit a 52-week high or low so far today.
52-Week High:
Rite Aid Corp. (NYSE: RAD) $2.15. Rite Aid blasting over 20 percent to a new annual high today after issuing...
Benzinga
Apr 11
Comment
Affymax, Inc (NASDAQ: AFFY) shares dropped 0.32% to create a new 52-week low of $6.23. Affymax said that the recall of Omontys has significantly hurt the company and it was considering all possible strategic alternatives, including restructuring...
StreetInsider.com
Apr 4
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Affymax+%28AFFY%29+Pays+Off+Oxford+Finance+Obligation/8234613.html for the full story.
Benzinga
Apr 2
Comment
Ian Somaiya, an analyst at Piper Jaffray, is suggesting that Affymax (NASDAQ: AFFY) may run out of cash sometime in mid-2012.
Somaiya reasons that Affymax has no timeline for potential re-introduction of Omontys and isn't able to estimate when...
Benzinga
Apr 2
Comment
Affymax (NASDAQ: AFFY) is down big on Tuesday after wildly missing the mark on its fourth quarter and 2012 earnings.
The Palo Alto, California firm posted a fourth quarter loss of $1.85 per share, down 126 percent year-over-year. This was far...
Suggest other news sources for this topic
more ▼WIKI ANALYSIS
WIKI ANALYSIS|
Error creating thumbnail: convert: unable to open image `/home/wikinvest/src_live_2/mediawiki/images/9/98/New_stock.png': No such file or directory @ blob.c/OpenBlob/2480. convert: unable to open file `/home/wikinvest/src_live_2/mediawiki/images/9/98/New_stock.png' @ png.c/ReadPNGImage/2889. convert: missing an image filename `/home/wikinvest/src_live_2/mediawiki/images/thumb/9/98/New_stock.png/35px-New_stock.png' @ convert.c/ConvertImageCommand/2800. |
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article. |
References
| |||||||
